JP2022520572A - 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 - Google Patents

免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 Download PDF

Info

Publication number
JP2022520572A
JP2022520572A JP2021547075A JP2021547075A JP2022520572A JP 2022520572 A JP2022520572 A JP 2022520572A JP 2021547075 A JP2021547075 A JP 2021547075A JP 2021547075 A JP2021547075 A JP 2021547075A JP 2022520572 A JP2022520572 A JP 2022520572A
Authority
JP
Japan
Prior art keywords
antibody
seq
light chain
amino acid
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021547075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520572A5 (https=
JPWO2020167376A5 (https=
Inventor
レイモンド コメンゾ，
ワグナー ザーゴ，
ニーナ メルセデス アシュトン，
Original Assignee
プロシーナ バイオサイエンシーズ リミテッド
タフツ メディカル センター インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロシーナ バイオサイエンシーズ リミテッド, タフツ メディカル センター インコーポレイテッド filed Critical プロシーナ バイオサイエンシーズ リミテッド
Publication of JP2022520572A publication Critical patent/JP2022520572A/ja
Publication of JP2022520572A5 publication Critical patent/JP2022520572A5/ja
Publication of JPWO2020167376A5 publication Critical patent/JPWO2020167376A5/ja
Priority to JP2024197437A priority Critical patent/JP2025015588A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021547075A 2019-02-12 2019-12-16 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 Withdrawn JP2022520572A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024197437A JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804721P 2019-02-12 2019-02-12
US62/804,721 2019-02-12
PCT/US2019/066648 WO2020167376A1 (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024197437A Division JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置

Publications (3)

Publication Number Publication Date
JP2022520572A true JP2022520572A (ja) 2022-03-31
JP2022520572A5 JP2022520572A5 (https=) 2022-12-22
JPWO2020167376A5 JPWO2020167376A5 (https=) 2022-12-22

Family

ID=69182616

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547075A Withdrawn JP2022520572A (ja) 2019-02-12 2019-12-16 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
JP2024197437A Pending JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024197437A Pending JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置

Country Status (17)

Country Link
US (2) US20220213223A1 (https=)
EP (1) EP3923954A1 (https=)
JP (2) JP2022520572A (https=)
KR (1) KR20210143752A (https=)
CN (2) CN119950702A (https=)
AU (2) AU2019429147B2 (https=)
BR (1) BR112021015870A2 (https=)
CA (1) CA3129890A1 (https=)
CL (1) CL2021002140A1 (https=)
EA (1) EA202192235A1 (https=)
IL (1) IL285480A (https=)
JO (1) JOP20210220A1 (https=)
MA (1) MA54923A (https=)
MX (1) MX2021009687A (https=)
PH (1) PH12021551960A1 (https=)
SG (1) SG11202108767PA (https=)
WO (1) WO2020167376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552135A1 (en) 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530917A (ja) * 2011-10-25 2014-11-20 オンクレーヴセラピューティクス リミテッド 抗体製剤および方法
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis
JP2018520101A (ja) * 2015-05-20 2018-07-26 ヤンセン バイオテツク，インコーポレーテツド 軽鎖アミロイドーシス及びその他のｃｄ３８陽性血液悪性疾患の治療のための抗ｃｄ３８抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530917A (ja) * 2011-10-25 2014-11-20 オンクレーヴセラピューティクス リミテッド 抗体製剤および方法
JP2018520101A (ja) * 2015-05-20 2018-07-26 ヤンセン バイオテツク，インコーポレーテツド 軽鎖アミロイドーシス及びその他のｃｄ３８陽性血液悪性疾患の治療のための抗ｃｄ３８抗体
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEUKEMIA, vol. 33, JPN6023049742, September 2018 (2018-09-01), pages 531 - 536, ISSN: 0005209499 *
MORIE A. GERTZ; ET AL: "FIRST-IN-HUMAN PHASE I/II STUDY OF NEOD001 IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND 以下備考", JOURNAL OF CLINICAL ONCOLOGY, vol. VOL:34, NR:10, JPN5022005816, April 2016 (2016-04-01), US, pages 1097 - 1103, ISSN: 0005209498 *

Also Published As

Publication number Publication date
MA54923A (fr) 2021-12-22
CN119950702A (zh) 2025-05-09
BR112021015870A2 (pt) 2021-11-03
MX2021009687A (es) 2021-12-10
SG11202108767PA (en) 2021-09-29
IL285480A (en) 2021-09-30
JP2025015588A (ja) 2025-01-30
CA3129890A1 (en) 2020-08-20
CN113924099A (zh) 2022-01-11
AU2019429147A1 (en) 2021-09-09
US20220213223A1 (en) 2022-07-07
EP3923954A1 (en) 2021-12-22
PH12021551960A1 (en) 2022-07-18
WO2020167376A8 (en) 2020-10-29
CL2021002140A1 (es) 2022-04-18
AU2019429147B2 (en) 2024-11-14
EA202192235A1 (ru) 2022-01-19
WO2020167376A1 (en) 2020-08-20
JOP20210220A1 (ar) 2023-01-30
AU2025200997A1 (en) 2025-03-13
KR20210143752A (ko) 2021-11-29
US20250075007A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
JP2025015588A (ja) 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
CN114026126B (zh) 抗半乳糖凝集素-9抗体及其用途
JP7160533B2 (ja) 多発性骨髄腫（ｍｍ）の処置
JP2022121658A (ja) アミロイドーシスを処置するための組成物
BR112015006189B1 (pt) Uso de um anticorpo anti-gm-csf
WO2022109302A9 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
Ashfaque et al. Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
CN119031933B (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
WO2016003789A1 (en) Combination therapy
JP7217287B2 (ja) アミロイド症の処置および予防
EA047876B1 (ru) Лечение al-амилоидоза комбинацией моноклональных антител против легких цепей иммуноглобулина и молекул клеточной мембраны cd38 в продуцирующих антитела и других иммунных клетках
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2026026912A1 (zh) 抗体药物偶联物和抗vegf抗体的联合应用
CN121622859A (zh) TGF-β受体融合蛋白在制备治疗胃及胃食管结合部腺癌的药物中的用途
WO2025076389A1 (en) Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates
WO2025256641A1 (zh) 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤
HK40008815B (en) Compositions for treating amyloidosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241119

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241203